Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders
Provided By GlobeNewswire
Last update: Oct 9, 2025
– Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension –
– New analysis increases overall confidence in the Phase 2 trial results –
Read more at globenewswire.comNASDAQ:ATHE (10/15/2025, 11:33:32 AM)
5.06
+0.33 (+6.98%)
Find more stocks in the Stock Screener
ATHE Latest News and Analysis
